Serum erythropoietin levels in hemodialysed patients after administration of recombinant human erythropoietin

Pavlović-Kentera, V; Clemons, Gisela K.; Biljanović-Paunović, L; Marisavljević, Dragomir; Ležaić, Višnja; Pokrajac, M.; Lj, Djukanović

doi:10.1016/0753-3322(92)90068-i

Cited by 8 publications

(4 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Blood Hb concentration and reticulocyte count were more effectively improved by CSI than by SBI. These findings are in line with the report of PavlovicKentera et al (20) that a modest increase in serum EPO (30-60 mIU/ml) was sufficient to correct anemia in hemodialysed patients.…”

Section: Discussionsupporting

confidence: 82%

Therapeutic use of continuous subcutaneous infusion of recombinant human erythropoietin in malnourished predialysis anemic patients with diabetic nephropathy

Sohmiya

Kakiba

Kato

1998

European Journal of Endocrinology

View full text Add to dashboard Cite

We compared the effect of recombinant human erythropoietin (rhEPO) administration by continuous s.c. infusion (CSI) with that of a weekly bolus s.c. injection (SBI) in five malnourished predialysis anemic patients with diabetic nephropathy. rhEPO was either continuously infused at a flow rate of 6000 IU per week (36 IU/h) (CSI group) or injected s.c. at a dose of 6000 IU once a week (SBI group) for 4 weeks, in a cross-over comparative study with a washout period of 4 weeks. Mean Ϯ S.D. plasma EPO levels increased from a basal value of 18.0 Ϯ 4.9 mIU/ml to a steady state value of 70.5 Ϯ 38.9 mIU/ml 2 weeks after the start of CSI of rhEPO (P < 0.05). Increases in reticulocyte count above the basal value were greater in the CSI group than the SBI group at 3 weeks after the start of treatment (0.94 Ϯ 0.35% vs ¹0.03 Ϯ 0.46%, P < 0.05). Increases in Hb concentration above the basal value were much greater in the CSI group than the SBI group at 4 weeks after the start of treatment (2.56 Ϯ 0.77 g/dl vs 0.28 Ϯ 0.62 g/dl, P < 0.05). These findings suggest that rhEPO administration by CSI is more effective than by SBI for improving anemia in malnourished predialysis patients with diabetic nephropathy.

show abstract

Section: Discussionsupporting

confidence: 82%

Therapeutic use of continuous subcutaneous infusion of recombinant human erythropoietin in malnourished predialysis anemic patients with diabetic nephropathy

Sohmiya

Kakiba

Kato

1998

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…Pharmacokinetic investigations of epoetinalfa in healthy volunteers after intravenous injections have demonstrated more rapid elimination after multiple doses than after the first dose [18]. This observation is consistent with enhanced clearance as a possible explanation.…”

Section: Discussionsupporting

confidence: 73%

Decreasing Reticulocyte Counts Associated with Declining Post-Dose Erythropoietin Plasma Levels in Anaemia of Prematurity

Meister

Khoss²,

Burda³

et al. 1998

Neonatology

View full text Add to dashboard Cite

A prospective sequential, multicentre trial was conducted to determine the association between erythropoietin (EPO) plasma levels and the erythropoietic response to recombinant human erythropoietin (r-HuEPO) during long-term treatment of premature infants. Twenty-nine infants, gestational ages 26–34 weeks and postnatal ages more than 14 days, received 600 IU r-HuEPO per kg per week divided into three doses subcutaneously for haemoglobin levels less than 120 g/l or haematocrit less than 36% over a period of 4 weeks. Eight additional patients were studied for a total of 10 weeks. EPO plasma concentrations and haematologic parameters were measured prior to the onset of treatment and at 2-weekly intervals thereafter. Treatment with r-HuEPO resulted in a median increase in corrected reticulocyte counts of 2.5% (range 0.2–4.6%) above patient’s baseline, thereafter a decrease was observed. In the 8 patients followed for 10 weeks reticulocyte counts declined significantly during weeks 6–10 when compared with the first 4 weeks (p < 0.005). Median 72-hour post-dose EPO plasma levels increased significantly (p < 0.0001) to 57.3 mU/ml (range 5.0–160) above patient’s baseline after the first injection, but declined progressively thereafter until they approached baseline values at week 10. Conclusion: R-HuEPO treatment after the first month was associated with a decrease in post-injection plasma levels and a decrease in erythropoietic response. This decrease in erythropoietin’s efficacy and the decline observed in post-dose EPO plasma levels may be causally related.

show abstract

“…We have reported previously that continuous subcutaneous infusion of rhEPO effectively increased Hb concentrations, in spite of a small but consistent increase of plasma EPO levels (50 mU/ml) compared with a transient increase in plasma EPO in subcutaneous injection of the same dosage of rhEPO (Sohmiya et al ., 1998b). Pavlovic‐Kentera et al . (1992) reported that a modest increase in serum EPO levels (30–60 IU/l) was sufficient to correct anaemia in haemodialysed patients.…”

Section: Discussionmentioning

confidence: 99%

Effect of long‐term administration of recombinant human growth hormone (rhGH) on plasma erythropoietin (EPO) and haemoglobin levels in anaemic patients with adult GH deficiency

Sohmiya

Kato

2001

Clinical Endocrinology

View full text Add to dashboard Cite

We conclude that EPO secretion was stimulated in the initial 2 weeks after the start of CSI of rhGH in anaemic patients with adult GH deficiency. Increased Hb concentrations after long-term administration of rhGH might be explained by direct stimulatory effects of rhGH and IGF-I on erythroid cells, which was accompanied by suppressed EPO secretion, in combination with a more generalized indirect impact of rhGH on physical activety. These findings suggest a beneficial effect of rhGH replacement in anaemic patients with adult GH deficiency.

show abstract

Serum erythropoietin levels in hemodialysed patients after administration of recombinant human erythropoietin

Cited by 8 publications

References 16 publications

Therapeutic use of continuous subcutaneous infusion of recombinant human erythropoietin in malnourished predialysis anemic patients with diabetic nephropathy

Therapeutic use of continuous subcutaneous infusion of recombinant human erythropoietin in malnourished predialysis anemic patients with diabetic nephropathy

Decreasing Reticulocyte Counts Associated with Declining Post-Dose Erythropoietin Plasma Levels in Anaemia of Prematurity

Effect of long‐term administration of recombinant human growth hormone (rhGH) on plasma erythropoietin (EPO) and haemoglobin levels in anaemic patients with adult GH deficiency

Contact Info

Product

Resources

About